Boehringer’s Biosimilar could take a Chunk out of the Cancer Market

17/11/2016 - 2 minutes

Boehringer Ingelheim is getting ready to launch a biosimilar for Roche’s cancer blockbuster Avastin as soon as the patent expires. Can it overcome the fierce competition in a market expected to grow to 50% of the drug market by 2020?

Boehringer Ingelheim just announced results from a Phase I trial showing that its biosimilar candidate BI695502 is equivalent to Roche’s Avastin (bevacizumab), number 4 in the list of top-selling biologicals. BI’s candidate performance in comparison to Avastin is currently being evaluated in a Phase III trial to treat non-small cell lung cancer (NSCLC). Results are expected in 2019 when Avastin patents expire in the US, whereas Europe will have to wait until 2022.

Avastin, which made €6.9Bn in sales last year, is an antibody drug that inhibits vascular endothelial growth factor A (VEGF-A) to block angiogenesis, a hallmark of cancer. The success of the drug relies on its multiple oncology indications: NSCLC, metastatic colorectal, metastatic kidney, ovarian, cervix and brain cancer.

However, BI is not the only one after Avastin’s pile of cash: Amgen just filed for FDA approval a biosimilar developed in partnership with Allergan,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member